Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Incyte Corporation

Market Cap 21.68B 18.69B 17.2B 16.13B 30.31B 2,049B 30.61B 203B 79.42B 1,003B 81.37B 79.64B 3,472B P/E Ratio 2026 *
16.5x
P/E Ratio 2027 * 14.1x
Enterprise Value 16.7B 14.39B 13.25B 12.43B 23.34B 1,578B 23.58B 157B 61.17B 773B 62.67B 61.34B 2,675B EV / Sales 2026 *
2.97x
EV / Sales 2027 * 2.37x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day-5.59%
1 week+2.13%
Current month+6.24%
1 month+7.84%
3 months+10.52%
6 months+4.20%
Current year+4.06%
1 week 101.51
Extreme 101.51
110.34
1 month 92.18
Extreme 92.18
110.34
Current year 89.25
Extreme 89.25
112.29
1 year 66.74
Extreme 66.7401
112.29
3 years 50.27
Extreme 50.27
112.29
5 years 50.27
Extreme 50.27
112.29
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
06-08Free

Director

7,753 0.0039%
06-08
FBS Associates LLC
OtherCompany 0 0%
06-08
Baker Bros. Advisors LP
FreeCompany 15,506 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
-5.56%+2.13%+44.31%+64.24% 21.68B
+0.11%+0.33%+17.35%-21.67% 62.28B
-5.71%-0.69%+60.05%+205.66% 60.59B
+2.86%+33.20%+33.20%+33.20% 39.55B
-1.84%+7.78%-55.82%-63.26% 36.8B
-0.97%+2.85%+51.18%-33.48% 29.53B
+1.51%+6.89%+95.69%-60.86% 19.8B
+1.24%+1.04%-4.09%+126.32% 16.96B
-0.96%-2.03%+50.73%+97.91% 16.16B
-0.82%+8.02%+149.78%+200.13% 13.13B
Average -1.03%+3.58%+44.24%+54.82% 31.65B
Weighted average by Cap. -1.35%+3.06%+34.95%+49.44%

Financials

2026 *2027 *
Net sales 5.63B 4.85B 4.47B 4.19B 7.87B 532B 7.95B 52.79B 20.62B 261B 21.12B 20.68B 902B 6.27B 5.4B 4.97B 4.67B 8.76B 593B 8.85B 58.8B 22.97B 290B 23.53B 23.03B 1,004B
Net income 1.37B 1.18B 1.08B 1.02B 1.91B 129B 1.93B 12.81B 5B 63.22B 5.13B 5.02B 219B 1.61B 1.39B 1.28B 1.2B 2.26B 152B 2.28B 15.13B 5.91B 74.66B 6.05B 5.93B 258B
Net Debt -4.98B -4.29B -3.95B -3.71B -6.96B -471B -7.03B -46.72B -18.25B -231B -18.7B -18.3B -798B -6.83B -5.89B -5.42B -5.08B -9.55B -645B -9.64B -64.05B -25.02B -316B -25.63B -25.09B -1,094B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
15/06/26 102.64 $ -5.43% 1,096,458
12/06/26 108.53 $ +0.65% 1,488,907
11/06/26 107.83 $ +2.32% 2,318,442
10/06/26 105.39 $ +2.09% 2,654,379
09/06/26 103.23 $ +2.57% 2,318,919
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
108.53USD
Average target price
109.09USD
Spread / Average Target
+0.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!